Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for seniors with rare blood cancer: gentler chemo shows promise

NCT ID NCT07535762

Not yet recruiting Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Apr 24, 2026 · Last updated May 16, 2026 · Updated 3 times

Summary

This study tests a new chemotherapy combination called CAOP for elderly patients (65+) with a rare type of lymphoma called peripheral T-cell lymphoma (PTCL). The goal is to see if replacing a standard drug with a less heart-toxic one can still effectively control the cancer while reducing side effects. About 36 participants will receive up to 6 cycles of treatment, and researchers will track how many achieve complete remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA (PTCL NOS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ruijin Hospital Wuxi Branch

    Wuxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ALK-1 NEGATIVE) NODAL T-FOLLICULAR HELPER CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA (PTCL NOS)